Clinical Trials

Title   Alliance Prospect
Principal Investigator/ Physician   Moh’d Khushman, MD
Protocol No.   N1048
Open Date   12/03/2015
Gender   Both
Cancer Site   Rectal
Status   Open
Sponsor   Alliance for Clinical Trials in Oncology
Contact Email   MCI Clinical Trials
Summary  

Protocol Title:  "A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiationversus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)."

Inclusion Criteria: Diagnosis of rectal adenocarcinoma, the standard treatment recommendation in the absence of a clinical trial would be combined modality neoadjuvant chemoradiation followed by curative intent surgical resection.

Exclusion Criteria: Clinical T4 tumors, Evidence that the tumor is adherent to or invading the mesorectal fascia on imaging studies such that the surgeon would not be able to perform an RO resection (one with negative margins). Chemotherapy within 5 years prior to registration, Exceptions are colonic polyps, non-melanoma skin cancer or carcinoma-in-situ of the cervix

Clinical Trails.Gov Link:    https://clinicaltrials.gov/ct2/show/NCT01515787?term=n1048&rank=1

Email Newsletters

Connect With Us